VIM and pancreatic neoplasm: In this paper, we evaluated the efficacy of isolating CTCs from the blood of patients with prostate and pancreatic cancer using EpCAM (an epithelial marker) and vimentin (a mesenchymal marker) antibodies individually and in combination.